Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2021Cited by 226
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatmentFederica Miglietta, Maria Vittoria Dieci, Valentina Guarneri et al.|npj Breast Cancer|2022Cited by 100
Immune characterization of breast cancer metastases: prognostic implicationsMaria Vittoria Dieci, Valentina Guarneri, Guido Ficarra et al.|Breast Cancer Research|2018Cited by 89
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III DiseaseMaria Vittoria Dieci, Valentina Guarneri, Vassilena Tsvetkova et al.|Frontiers in Oncology|2019Cited by 71
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implicationsGaia Griguolo, Valentina Guarneri, Michele Bottosso et al.|Cancer Treatment Reviews|2021Cited by 42